Drug Abuse Treatment Market By Treatment Type (Medication-Assisted Treatment, Behavioral Therapy, Detoxification, Inpatient Rehabilitation, Outpatient Rehabilitation, Others), By Substance Type (Alcohol, Opioids, Marijuana, Cocaine, Prescription Drugs, Others), By End-User Industry (Hospitals & Clinics, Rehabilitation Centers, Residential Treatment Centers, Outpatient Counseling Centers, Others), and By Therapy Type (Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, Contingency Management, Motivational Interviewing, Family Therapy, Others); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Drug Abuse Treatment Market was valued at USD 9.3 billion in 2023 and will surpass USD 17.0 billion by 2030; growing at a CAGR of 9.1% during 2024 - 2030.

The drug abuse treatment market is expanding rapidly as the global incidence of substance abuse continues to rise. This market encompasses a wide array of treatments and services designed to help individuals overcome addiction, regain control over their lives, and prevent relapse. With increasing awareness of the detrimental effects of drug abuse on both individuals and society, the demand for effective treatment methods is growing. The treatment landscape includes various approaches such as medication-assisted treatment (MAT), behavioral therapies, detoxification, and rehabilitation services. This diverse range of options caters to different substances and treatment needs, ensuring a holistic approach to addiction recovery.

Medication-Assisted Treatment (MAT) Segment Is Largest Owing to Its Effectiveness in Treating Opioid Addiction

Medication-Assisted Treatment (MAT) is the largest segment within the drug abuse treatment market due to its proven success in treating opioid addiction. MAT involves the use of medications like methadone, buprenorphine, and naltrexone combined with counseling and behavioral therapies. It has become a critical part of opioid use disorder treatment, particularly in North America, where the opioid crisis is most severe. MAT helps reduce cravings and withdrawal symptoms, making it an essential treatment for individuals suffering from opioid addiction. As opioid abuse continues to rise globally, MAT remains the cornerstone of treatment programs for opioid dependence, significantly contributing to the segment's dominance in the market.

Opioids Remain the Leading Substance Type Driving Treatment Demand

Opioids are the leading substance type contributing to the growth of the drug abuse treatment market. The opioid epidemic, particularly in North America, has resulted in a massive surge in demand for addiction treatment services. Opioid-related overdoses have become a public health crisis, prompting the widespread adoption of MAT and other addiction treatment services. Opioids, including prescription painkillers, heroin, and fentanyl, account for a significant share of drug abuse cases. The increasing prevalence of opioid addiction is a key factor in the expansion of the treatment market, as healthcare providers continue to develop more advanced therapies and intervention strategies tailored to opioid addiction recovery.

Rehabilitation Centers Are Leading the End-User Industry

Rehabilitation centers are the largest end-user industry in the drug abuse treatment market, offering both inpatient and outpatient services for addiction recovery. These centers provide specialized programs that combine medical, therapeutic, and social support for individuals struggling with substance abuse. Rehabilitation centers are equipped with trained professionals who use various treatment methods, including detoxification, cognitive behavioral therapy (CBT), and MAT, to help patients recover from addiction. The rising demand for comprehensive care and support services in a structured environment has made rehabilitation centers the primary choice for individuals seeking treatment, solidifying their position as a leading segment in the market.

Cognitive Behavioral Therapy (CBT) Is the Fastest-Growing Therapy Type

Cognitive Behavioral Therapy (CBT) is the fastest-growing therapy type within the drug abuse treatment market. CBT focuses on changing negative thought patterns and behaviors that contribute to addiction. It has gained popularity due to its structured and goal-oriented approach, which has been shown to be highly effective in treating various substance use disorders. CBT helps individuals develop healthier coping mechanisms and learn how to handle stress and triggers that may lead to relapse. As more individuals seek evidence-based, short-term therapies, CBT has emerged as a preferred choice in both inpatient and outpatient settings, fueling its rapid growth within the drug abuse treatment landscape.

North America Is the Largest Region for Drug Abuse Treatment Market

North America remains the largest region for the drug abuse treatment market, primarily due to the ongoing opioid crisis and the region's robust healthcare infrastructure. The U.S. accounts for a significant share of the market, with a high prevalence of drug abuse cases, particularly opioid addiction. Government initiatives, such as funding for addiction recovery programs and the availability of MAT services, have contributed to the growth of the market in this region. Additionally, the rising awareness about mental health and addiction has driven individuals to seek treatment, further boosting the demand for drug abuse treatment services in North America. The region's extensive network of rehabilitation centers, hospitals, and outpatient counseling services continues to support its dominant position in the market.

Leading Companies and Competitive Landscape

The drug abuse treatment market is highly competitive, with a number of established pharmaceutical companies, rehabilitation centers, and healthcare providers dominating the landscape. Leading companies in this space include Pfizer Inc., Johnson & Johnson, Reckitt Benckiser, Indivior PLC, and AbbVie Inc. These companies are focused on expanding their portfolios of addiction treatment medications, such as methadone, buprenorphine, and naltrexone, to cater to the growing demand for MAT services. Additionally, behavioral therapy providers are increasingly adopting evidence-based approaches, such as CBT and DBT, to enhance their treatment offerings.

The competitive landscape is also shaped by rehabilitation centers and healthcare providers that offer a wide range of addiction recovery services, including inpatient and outpatient rehabilitation programs. The market is marked by a combination of pharmaceutical companies developing new treatment options, as well as specialized treatment centers expanding their reach and capabilities to meet the rising demand for drug abuse treatment services. Partnerships, mergers, and acquisitions are also common, as companies look to strengthen their market position and expand their treatment offerings.

Recent Developments:

• Pfizer recently announced the launch of a new opioid addiction treatment medication, adding to their portfolio of MAT drugs. This launch is expected to enhance their market presence in the opioid treatment segment.
• Indivior PLC recently received approval from the FDA for a new formulation of Suboxone, aimed at improving patient adherence to opioid addiction treatment programs.
• Teva Pharmaceuticals has partnered with several nonprofit organizations to expand access to addiction recovery services, particularly in underserved communities.
• Mylan announced the launch of a generic version of Buprenorphine, a medication used in MAT for opioid addiction, aiming to increase accessibility and affordability.
• Reckitt Benckiser has increased efforts to distribute its addiction treatment products globally, particularly in emerging markets where drug abuse is becoming a significant concern

List of Leading Companies:

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Reckitt Benckiser Group
• Akorn, Inc.
• AbbVie Inc.
• GlaxoSmithKline
• Mallinckrodt Pharmaceuticals
• Indivior PLC
• Teva Pharmaceuticals
• Eli Lilly and Co.
• The Medicines Company
• Otsuka Pharmaceutical Co., Ltd.
• Kaiser Permanente

Report Scope: